CDR-Life AG

Recent Finacing

Series A

Recent Raise

$76M

CDR‑Life develops M-gager® MHC-targeting T cell engagers for intracellular cancer antigens, advancing CDR404 (dual MAGE‑A4), CDR101 (BCMA/CD3/PD-L1), and partnered CDR202 for macular degeneration.

Founded 2017

Zurich, Switzerland

51-100

Private

cdr-life.com

Highlights

Focus Areas

Biotechnology

Oncology

Recent Investors

Financials

$76M

Total Raised

1

Funding round

3

Investors

Team

Upgrade to view the team

See the team members at CDR-Life AG.